Avadel Pharmaceuticals Q3 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $50.025M Beat $48.607M Estimate
Avadel Pharmaceuticals Q3 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $50.025M Beat $48.607M Estimate
avadel pharmaceuticals 2024年第三季度 GAAP 每股收益 $(0.03)，超出 $(0.06) 估計，銷售額 $5002.5萬，超出 $4860.7萬 估計
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 92.68 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $50.025 million which beat the analyst consensus estimate of $48.607 million by 2.92 percent. This is a 613.22 percent increase over sales of $7.014 million the same period last year.
Avadel Pharmicals（納斯達克股票代碼：AVDL）公佈的季度虧損爲每股0.03美元，比分析師普遍預期的0.06美元（0.06美元）高出50％。與去年同期每股虧損0.41美元（0.41美元）相比，增長了92.68％。該公司公佈的季度銷售額爲5,025萬美元，比分析師普遍預期的4,860.7萬美元高出2.92％。這比去年同期701.4萬美元的銷售額增長了613.22％。
資訊熱榜
更新時間